Results 51 to 60 of about 2,105 (188)

Marimastat

Drugs in R & D, 2003
Marimastat [BB 2516, TA 2516] is a second-generation anticancer drug originally developed with British Biotech in Europe and North America. It is an orally active metalloprotease inhibitor of the same class as batimastat, and is the first compound in this class to have completed a pivotal clinical trial.
openaire   +2 more sources

Engineering Antivenom: Research Progress and Future Directions in Snakebite Envenoming Therapy

Annals of the New York Academy of Sciences, Volume 1562, Issue 1, August 2026.
Snakebite envenoming therapy is evolving from plasma‐derived antivenoms toward rationally engineered therapeutics. Advances in toxicovenomics, structural biology, antibody engineering, computational protein design, recombinant expression, small‐molecule inhibitors, and diagnostics are enabling toxin‐centric development of safer, more effective, and ...
Andreas H. Laustsen
wiley   +1 more source

Marimastat treatment ameliorated hepatic injury and the inflammatory response following repeated carbon tetrachloride (CCl4) administration.

, 2013
Marimastat treatment significantly reduced serum alkaline phosphatase levels (A), and resulted in a 14-fold decrease of serum ALT (B), indicating decreased hepatic injury.
Hau D. Le (343378), Vincent E. de Meijer (343377), Deanna Y. Sverdlov (363722), Yury Popov (343381), Detlef Schuppan (204756), Vânia Nosé (5653522), Mark Puder (343382), Jonathan A. Meisel (343379)   +7 more
core   +1 more source

Recent Advances in Next Generation Snakebite Antivenoms

Tropical Medicine and Infectious Disease, 2018
With the inclusion of snakebite envenoming on the World Health Organization’s list of Neglected Tropical Diseases, an incentive has been established to promote research and development effort in novel snakebite antivenom therapies.
Cecilie Knudsen, Andreas H. Laustsen
doaj   +1 more source

Endometriosis: Epidemiology, Risk Factors, Molecular Mechanisms, Diagnosis, and Management

MedComm, Volume 7, Issue 7, July 2026.
Global epidemiology, integrated determinants, and disease burden of endometriosis. This circular schematic comprehensively illustrates the global prevalence and demographic variation of endometriosis, its multifactorial integrated determinants, the multifaceted disease burden and economic impact, and recent epidemiological trends, providing a holistic ...
Kun Wang, Dongyun He, Yang Wang, Xiaojun Liu, Li Liu   +4 more
wiley   +1 more source

CD31 and α-SMA staining in the lung of infected mice treated with Marimastat.

, 2018
(A): Mice infected with Mtb were treated with PBS (n = 5) or Marimastat (n = 5). Lung tissue from infected mice was stained for CD31 (upper panel) and α-SMA (lower panel). Both PBS and Marimastat groups had positive staining of CD31 and α-SMA. Scale bar:
Veronique Dartois (2283115), Lu Huang (211625), Yitian Xu (5146028), Xiling Shen (184092), Evgeniya V. Nazarova (5146040), Pengcheng Bu (5146031), David G. Russell (156949), Matthew D. Zimmerman (1604746), Nikolai Rakhilin (5146037), Kai-Yuan Chen (5146034), Dah-Jiun Fu (5146025), Lihua Wang (14548), Firat Kaya (2919981)   +12 more
core   +1 more source

A guide to the types, structures, and multifaceted functions of matrix metalloproteinases in cancer

The FEBS Journal, Volume 293, Issue 13, Page 3717-3757, July 2026.
Matrix metalloproteinases (MMPs) orchestrate cancer progression and metastasis through proteolytic and non‐proteolytic actions. By remodeling the tumor microenvironment, enhancing growth factor availability, and modulating cell behavior, MMPs promote proliferation, migration or invasion, and epithelial‐to‐mesenchymal transition. Alongside extracellular
Zoi Piperigkou, Sylvia Mangani, Spyros Kremmydas, Nikolaos E. Koletsis, Nikos K. Karamanos   +4 more
wiley   +1 more source

Proteolysis at the extracellular matrix interface: Molecular architects and regulators in health and disease

The FEBS Journal, Volume 293, Issue 13, Page 3758-3787, July 2026.
The extracellular matrix (ECM) is a dynamic scaffold that orchestrates tissue architecture and cellular communication. A critical but underexplored interplay between proteases and cluster of differentiation molecules (CD) governs ECM turnover and directs cell fate.
David Jurnečka, Matija Hrovatin, Bor Bokalj, Boris Turk   +3 more
wiley   +1 more source

The Relative Efficacy of Chemically Diverse Small-Molecule Enzyme-Inhibitors Against Anticoagulant Activities of African Spitting Cobra (Naja Species) Venoms

Frontiers in Immunology, 2021
African spitting cobras are unique among cobras for their potent anticoagulant venom activity arising from strong inhibition of Factor Xa. This anticoagulant effect is exerted by venom phospholipase A2 (Group I PLA2) toxins whose activity contributes to ...
Abhinandan Chowdhury, Abhinandan Chowdhury, Matthew R. Lewin, Matthew R. Lewin, Christina N. Zdenek, Rebecca Carter, Bryan G. Fry   +6 more
doaj   +1 more source

When proteases reshape barriers: Basement membrane remodelling in development, wound healing and tumour progression

The FEBS Journal, Volume 293, Issue 13, Page 3954-3972, July 2026.
Basement membrane (BM) homeostasis relies on a balance between integrity, controlled remodelling and pathological degradation. Increased protease expression beneath the BM, along with reduced levels of endogenous protease inhibitors, drives the transition from a continuous, protective barrier to a discontinuous interface.
Clara Legendre, Guila Dayan, Patricia Rousselle   +2 more
wiley   +1 more source